Basilea supported by CARB-X funding
CARB-X is awarding Swiss listed company Basilea Pharmaceutica International up to US $2.7m to develop a novel class of antibiotics to treat Gram-negative bacterial infections.
The project aims to develop selective small-molecule inhibitors of 1-deoxy-D-xylulose 5-phosphate reductor isomerase (DXR), an enzyme in the bacterial isoprenoid biosynthesis pathway that is essential for the survival of many drug-resistant pathogens, including carbapenem-resistant Enterobacterales (CRE), Acinetobacter baumannii and multidrug-resistant (MDR) Pseudomonas aeruginosa.
“The Basilea project is in the early stages of development, with a novel chemical class working with a novel mechanism of inhibition of bacterial growth. Together, these offer a potential advantage where the development of resistance is concerned and – as such – offer great promise for a new therapy to treat serious hospital infections,” says Erin Duffy, R&D Chief of CARB-X.
For more information, please see here: https://carb-x.org/carb-x-news/carb-x-is-funding-basilea-pharmaceutica-to-develop-a-new-class-of-antibiotics-to-treat-drug-resistant-gram-negative-bacteria/